ArticleAngewandte Chemie (International ed. in English)2020
Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes.
Article in Angewandte Chemie (International ed. in English), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Rhenium(I) tricarbonyl complexes with 1,10-phenanthroline derivatives: potential anticancer agents for hepatocellular carcinoma.Frontiers in pharmacology · 2026Article
- Novel Re(I) Complexes as Potential Selective Theranostic Agents in Cancer Cells andJournal of medicinal chemistry · 2024Article
- Role of Pure Technetium Chemistry: Are There Still Links to Applications in Imaging?Inorganic chemistry · 2023Article
- An Anticancer Rhenium Tricarbonyl Targets Fe-S Cluster Biogenesis in Ovarian Cancer Cells.Angewandte Chemie (International ed. in English) · 2022Article
- Photoinduced Processes in Rhenium(I) Terpyridine Complexes Bearing Remote Amine Groups: New Insights from Transient Absorption Spectroscopy.Molecules (Basel, Switzerland) · 2022Article
- Controlling of Photophysical Behavior of Rhenium(I) Complexes with 2,6-Di(thiazol-2-yl)pyridine-Based Ligands by Pendant π-Conjugated Aryl Groups.International journal of molecular sciences · 2022Article
- Target-specific mononuclear and binuclear rhenium(i) tricarbonyl complexes as upcoming anticancer drugs.RSC advances · 2022Review
- Real-time tracking of ER turnover during ERLAD by a rhenium complex via lifetime imaging.National science review · 2022Article
- Cycloruthenated Self-Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers.Advanced materials (Deerfield Beach, Fla.) · 2022Article
- Label-Free Target Identification Reveals the Anticancer Mechanism of a Rhenium Isonitrile Complex.Frontiers in chemistry · 2022Article
- Metal Complexes for Therapeutic Applications.Trends in chemistry · 2021Article
- Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Review
- Phosphorescent metal complexes as theranostic anticancer agents: combining imaging and therapy in a single molecule.Chemical science · 2021Review
- Influence of the Nucleophilic Ligand on the Reactivity of Carbonyl Rhenium(I) Complexes towards Methyl Propiolate: A Computational Chemistry Perspective.Molecules (Basel, Switzerland) · 2020Article
- Exploring the In Vivo and In Vitro Anticancer Activity of Rhenium Isonitrile Complexes.Inorganic chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Rhenium tricarbonyl complexes have been recently investigated as novel anticancer agents. However, little is understood about their mechanisms of action, as well as the means by which cancer cells respond to chronic exposure to these compounds. To gain a deeper mechanistic insight into these rhenium anticancer agents, we developed and characterized an ovarian cancer cell line that is resistant to a previously studied compound [Re(CO)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.